Initial Hepatitis Virus Testing in Transaminitis
All patients presenting with transaminitis should undergo first-line testing for hepatitis A, B, C, and E simultaneously, as hepatitis E is now recognized as the most common cause of acute viral hepatitis in many developed countries and should not be relegated to second-line testing. 1
Core First-Line Serologic Panel
Hepatitis B Testing
- HBsAg (Hepatitis B surface antigen): Detects current HBV infection 2
- Anti-HBc IgM (Hepatitis B core antibody, IgM): Distinguishes acute from chronic HBV infection 2
- Anti-HBc total (IgG): May be the only positive marker during the "window phase" of acute hepatitis B or in occult hepatitis B 2
Hepatitis C Testing
- Anti-HCV antibody: Initial screening test for HCV exposure 3, 4
- HCV RNA (nucleic acid test): Must be performed reflexively on the same sample if anti-HCV is reactive, without requiring a second venipuncture 3, 4, 5
Hepatitis A Testing
- Anti-HAV IgM: Detects acute hepatitis A infection 2
Hepatitis E Testing
- Anti-HEV antibody (IgM and IgG): Should be performed at presentation, not as second-line testing 1
- HEV RNA (nucleic acid test): Recommended in combination with serology for optimal diagnostic accuracy 1
- This represents a major paradigm shift: hepatitis E testing is no longer reserved for travelers to endemic areas, as most cases in developed countries are locally acquired 1
Critical Testing Sequence for Hepatitis C
The CDC-recommended approach requires a specific two-step process 4, 5:
- Initial anti-HCV antibody test (reactive or nonreactive) 4, 5
- Immediate reflex to HCV RNA testing on the same blood sample if antibody is reactive 4, 5
Interpretation:
- HCV RNA detected = Current infection requiring treatment 4, 5
- HCV RNA not detected = Past resolved infection or false-positive antibody 4, 5
Additional Hepatitis B Markers for Chronic Infection
If HBsAg is positive, add 2:
- HBeAg/anti-HBe: Determines replication status and guides treatment decisions 2
- HBV DNA quantitative: Essential for distinguishing chronic hepatitis B from inactive carrier state 2
Special Circumstances Requiring Modified Approach
Immunocompromised Patients
- Consider HCV RNA testing even with negative antibody, as antibody response may be blunted 4, 5
- Test for HEV RNA in addition to serology, as chronic HEV infection occurs in this population and can cause cryptogenic cirrhosis 1, 6
- Isolated anti-HBc positivity may indicate occult hepatitis B; measure HBV DNA if this pattern is found 2
Recent Exposure (Within 6 Months)
- Repeat HCV RNA or anti-HCV testing even if initial tests are negative, as antibodies may not yet be detectable 4, 5
- IgM anti-HBc is essential for diagnosing acute hepatitis B during the window phase when HBsAg may be negative 2
Drug-Induced Liver Injury (DILI) Suspected
- Always test for hepatitis E, as 13% of presumed DILI cases in one UK cohort were actually acute hepatitis E 1
- This is particularly important in elderly patients with polypharmacy, as both DILI and hepatitis E are most common in this population 1
Common Pitfalls to Avoid
- Never report reactive HCV antibody as "hepatitis C infection" without RNA confirmation—this only indicates exposure, not current infection 4, 5
- Do not defer hepatitis E testing to second-line evaluation or limit it to travelers; local acquisition is now the predominant pattern in developed countries 1
- Do not rely on transaminase levels to exclude significant liver disease—50% of HCV-infected patients have normal ALT values despite histologic disease 7
- Do not assume isolated anti-HBc positivity is a false positive—measure HBV DNA to exclude occult hepatitis B 2
Co-infection Screening
In appropriate risk groups, test for 2: